Theravance Biopharma Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '25 Dec 4, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Market Capitalization	808	447	506	706	716	929	Upgrade
Market Cap Growth	75.39%	-11.74%	-28.28%	-1.40%	-22.96%	-29.02%	Upgrade
Enterprise Value	560	402	431	299	1,116	1,143	Upgrade
Last Close Price	15.90	9.10	10.20	10.40	9.30	14.40	Upgrade
PE Ratio	32.31	-	-	0.87	-	-	Upgrade
PS Ratio	11.80	7.19	9.75	14.70	14.72	15.82	Upgrade
PB Ratio	4.07	2.64	2.63	1.71	-2.40	-3.74	Upgrade
P/TBV Ratio	4.07	2.64	2.63	1.71	-	-	Upgrade
EV/Sales Ratio	8.12	6.47	8.30	6.23	22.95	19.46	Upgrade
Debt / Equity Ratio	0.19	0.28	0.23	0.12	-1.98	-2.23	Upgrade
Asset Turnover	0.21	0.18	0.12	0.11	0.13	0.16	Upgrade
Quick Ratio	9.30	4.89	4.84	11.99	3.20	2.93	Upgrade
Current Ratio	9.48	5.02	5.39	12.31	4.26	3.18	Upgrade
Return on Equity (ROE)	14.03%	-29.04%	-16.86%	-179.84%	-	-	Upgrade
Return on Assets (ROA)	-5.32%	-7.21%	-6.78%	-10.07%	-35.20%	-42.38%	Upgrade
Return on Capital (ROIC)	-8.08%	-10.88%	-8.87%	-11.99%	-42.23%	-56.44%	Upgrade
Return on Capital Employed (ROCE)	-8.70%	-13.20%	-15.00%	-13.70%	-75.10%	-86.10%	Upgrade
Earnings Yield	3.10%	-12.19%	-9.86%	115.58%	-24.49%	-24.45%	Upgrade
FCF Yield	25.68%	-2.56%	-5.27%	-24.86%	-25.94%	-22.61%	Upgrade
Buyback Yield / Dilution	-3.49%	11.67%	24.85%	-5.95%	-11.41%	-12.11%	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.